


SARS-CoV-2 Sequencing Update 29 April 2022



Prepared by the National Institute for Communicable Diseases (NICD) of the National Health Laboratory (NHLS) on behalf of the Network for Genomics Surveillance in South Africa (NGS-SA)


Department Science and Innovation The genomic data presented here are based on South African SARS-CoV-2 sequence data downloaded from GISAID (www.gisaid.org) on 29 April 2022 at 14h25



Data license: https://www.gisaid.org/registration/terms-of-use/

Elbe, S., and Buckland-Merrett, G. (2017) Data, disease and diplomacy: GISAID's innovative contribution to global health. Global Challenges, 1:33-46. DOI: 10.1002/gch2.1018 PMCID: 31565258

Shu, Y., McCauley, J. (2017) GISAID: Global initiative on sharing all influenza data – from vision to reality. EuroSurveillance, 22(13) DOI: 10.2807/1560-7917.ES.2017.22.13.30494 PMCID: PMC5388101




1 288 genomes deposited since the previous report

Surveillance in South Africa

Bar graphs represent genomes sequenced per epiweek, with lines representing cases by collection date (weeks 39 [2021] – 17 [2022])

Genomes and cases presented as provincial total (percentage of national total) for epiweeks 39 (2021) - 17 (2022)


PTP: percentage testing positive in week 16 (17 Apr 2022 – 23 Apr 2022); arrow indicates direction of change since previous week (10 Apr 2022 – 16 Apr 2022) if change was significant (P<0.05)



*This represents the cleaned, de-duplicated dataset of unique National and Pneumonia Surveillance sequences. This dataset will be used for all further figures.

GISAID genomes vs total cases, 2020 – 2022 (N=38 359)


Provincial breakdown of genomes deposited into GISAID



All provinces, apart from GP, KZN, LP, NC and WC, have comparable percentages of overall cases and overall sequenced genomes.




Number and percentage of clades by epiweek in South Africa, 2021 – 2022 (31 646*)



Delta dominated in South Africa until October at >80%. Omicron has dominated from November onwards.






February and March. BA.4 and BA.5 together are dominant in April (58.4%, 366/627).

NGS-SA Network for Genomic Surveillance in South Africa

Detection Rates: Beta, Delta, C.1.2 and Omicron

Detection rates of variants being monitored in South Africa




*Bars represent percentage prevalence of variant for the month; total number sequences collected for the month are given below the bar

Omicron has been dominant since November (>85% in November, >98% in December – April). BA.2 made up 43% of genomes in January, 86% in February, 78% in March and 39% in April. Newly designated sublineages BA.4 and BA.5 together are dominant in April, at 38% and 20% respectively.




South Africa, 2021-2022, n = 31646*




Surveillance in South Africa

*Excludes sequences missing collection dates, as well as those collected January 1st and 2nd 2021 as they are part of epiweek 53 of 2020.


Eastern Cape Province, 2021-2022, n = 2693




Free State Province, 2021-2022, n = 1437




Gauteng Province, 2021-2022, n = 8640




KwaZulu-Natal Province, 2021-2022, n = 3564




Limpopo Province, 2021-2022, n = 2411




Mpumalanga Province, 2021-2022, n = 2359




Northern Cape Province, 2021-2022, n = 1744



North West Province, 2021, n = 2011



Western Cape Province, 2021-2022, n = 6782




Summary

• Variant of Concern Omicron in South Africa

- Dominates 2022 sequencing data at >98% of genomes.
- While BA.1 (and sub-lineages) was the predominant sub-lineage in January (55%), BA.2 dominated in February (86%) and March (78%).
- Two additional Omicron sub-lineages (BA.4 and BA.5) have recently been designated. BA.4 and BA.5 increased in prevalence in March (16%), and together are dominant in April (58%).
 - These numbers are likely to change as new versions of the assignment tool are released.
- BA.3 continues to be detected at low levels.
- NGS-SA teams are monitoring sequencing data for recombinants.
- Low frequency of previously circulating variants such as Delta still detected in recent data



Omicron spike mutations compared to other VOC/VOIs



Only lineage-defining mutations are pictured here. Low prevalence mutations can be seen on the following slide.

Mutation impact key

Unknown or unconfirmed impactKnown/predicted immune escapeEnhanced infectivity

- Multiple changes within the two immunogenic regions in S1 (NTD and RBD)
 - including a three amino acid insertion
- Accumulation of mutations surrounding the furin cleavage site
 - Including combination of N679K and P681H
- Effect of most spike S2 subunit changes have not been defined, but may be linked to immune escape







NATIONAL HEALTH LABORATORY SERVICE

XX

ЕDСТР

3030) is part of the

EDCTP2 programme

University of Stellenbosch & NHLS Tygerberg Virology



Susan Engelbrecht Wolfgang Preiser Gert van Zyl Tongai Maponga **Bronwyn Kleinhans** Shannon Wilson Karabo Phadu Tania Stander Kamela Mahlakwane Mathilda Claassen **Diagnostic laboratory staff**

University of Cape Town, NHLS & Western Cape Government

health



NHLS-UCT

Carolyn Williamson

Nei-yuan Hsiao

Diana Hardie

Kruger Marais

Stephen Korsman

Ziyaad Valley-Omar

WCG-UCT Mary-Anne Davies Hannah Hussev Andrew Boulle Masudah Paleker Theuns Jacobs

Department. Health REPUBLIC OF SOUTH ATRICA

Erna Morden



UCT. IDM and CIDRI-Africa

Deelan Doolabh Arash Iranzadeh Lynn Tyers Innocent Mudau Wendy Burgers Nokuzola Mbhele Ntobeko Ntusi Fezokuhle Khumalo Rageema Joseph Thabang Serakge Sean Wasserman Bruna Galvão Linda Boloko Arghavan Alisoltani (U. California)

NHLS Greenpoint Annabel Enoch



Robert Wilkinson Darren Martin Nicola Mulder

Samrc

CAPE TOWN HVTN

ΧŻ

EDCTP

W

cience & innovation etrent: nos and knovation VELIC OF SOUTH AFRICA

UKZN-Inkosi Albert Luthuli Central Hospital



Dr Khanvi Msomi Dr Kerusha Govender Dr Tshepiso Mosito Dr Pravi Moodley Dr Aabida Khan Dr Lili Gounder Dr Kerri Francois Dr Cherise Naicker Dr Joedene Chetty

Zoonotic arbo and respiratory virus

program

Centre for Viral Zoonoses

Department Medical Virology/ NHLS

Tshwane Academic division

University of Pretoria

ZARV research program/UP

Adriano Mendes (Postdoc)

Amy Strydom (Postdoc)

Carien van Niekerk

NHLS Tshwane

Fabian Leendertz

Funders:

Marietjie Venter (Head: ZARV)

Prof Simnikiwe Mayaphi (HOD)

GIZ/BMBF: African Network for Improved

emerging infectious agents (ANDEMIA)

diagnostics and epidemiology of common and

G7 Global Health fund, Robert Koch Institute, Dr

Michaela Davis (MSc, intern medical scientist)

٩

UNIVERSITY OF INYUVES YAKWAZULU-NATALI

Dr Neli Ngcaba Mr Malcolm Ellapen Mr Kubendran Reddy The COVID-19 Bench team

University of KwaZulu-Natal & Africa **Health Research Institute**



Tulio de Oliveira Richard Lessels Houriivah Tegally Eduan Wilkinson Jennifer Giandhari Sureshnee Pillav **Emmanuel James San**

KRISP at UKZN:

AHRI **AHRT**AFRICA RESEARCH INSTITUTE Alex Sigal Sandile Cele Willem Hanekom

National Institute for Communicable Diseases

Jinal Bhiman

Thandeka Movo

Frances Ayres

Zanele Molaudzi

Bronwen Lambson

Tandile Hermanus

Prudence Kgagudi

Brent Oosthuysen

Penny Moore

Lynn Morris

NICD Groups

AFRICA CDC

Group

Mashudu Madzivhandila

NICD COVID-19 response team

NICD SARS-CoV-2 Sequencing

Tandile Hermanus



Centre for Respiratory Diseases & Meningitis Anne von Gottberg Thabo Mohale Daniel Amoako Josie Everatt Boitshoko Mahlangu Noxolo Ntuli Anele Mnguni Amelia Buys Cardia Fourie Noluthando Duma Linda de Gouveia Jackie Kleynhans Nicole Wolter Sibongile Walaza

Mignon du Plessis Stefano Tempia Mvuyo Makhasi Cheryl Cohen



Sequencing Core Facility Annie Chan Morne du Plessis Stanford Kwenda **Mushal Allam** Florah Mnyameni Arshad Ismail









Centre for HIV and STIs Zamantungwa Khumalo **Cathrine Scheepers Constantinos Kurt Wibmer** Phillip Senzo Mtshali









University of the

Free State

Dominique Goedhals Armand Bester Martin Myaga Peter Mwangi Emmanuel Ogunbayo Milton Mogotsi Makgotso Maotoana Lutfiyya Mohamed



NHLS Division of Virology Sabeehah Vawda Felicity Burt Thokozani Mkhize **Diagnostic laboratory staff**





Key to Diagnostic Excellent

ΑΜΡΑΤΗ

LABORATORIES

PathCare

1

Vermaak

africa

aboratorie

FIOCRUZ

NHLS Koeleka Mlisana Zinhle Makatini Eugene Elliot Florette K. Treurnicht Kathleen Subramoney Oluwakemi Laguda-Akingba Shareef Abrahams Greta Hoyland Gloria Selabe

Jeannette Wadula

Elias Bereda

Hyrax Biosciences Simon Travers

Cape Town HVTN Laboratory Erica Anderson-Nissen Anneta Naidoo

Ndlovu Research Hugo Tempelman CJ Umunnakwe **Lancet** Allison J. Glass Raquel Viana

Ampath Terry Marshall Cindy van Deventer Eddie Silberbauer

Pathcare Vermaak Andries Dreyer Howard Newman Riaan Writes Marianne Wolfaardt Warren Lowman

Bridge-the-Gap Raymond Rott

Cytespace Africa Laboratories Christa Viljoen

ARC-OVI Lia Rotherham **CAPRISA** Salim Abdool Karim Nigel Garret

Additional support and collaborators

UKZN - Big Data Francesco Pettruccione Ilya Sinayskiy

University of Oxford José Lourenço

FioCruz, Brazil Vagner Fonseca Marta Giovanetti Luiz Carlos Junior Alcantara **Africa CDC** John Nkengasong Sofonias Tessema

Netcare: Richard Friedland Craig Murphy Caroline Maslo Liza Sitharam

DSI

Glaudina Loots

SA MRC Glenda Gray


















South African genomes submitted per submitting lab, 2020 - 2022 (N=38 359)

Submitting labs in South Africa



NGS-SA Labs

CERI: Centre for Epidemic Response and Innovation KRISP: KZN Research Innovation and Sequencing Platform NDLOVU: Ndlovu Research Laboratories NICD: National Institute for Communicable Diseases NHLS: National Health Laboratory Service SU: Stellenbosch University UCT: University of Cape Town UFS: University of the Free State UP: University of Pretoria

Multiple labs from NGS-SA and collaborating public and private laboratories are contributing to sequencing, both as originating and as submitting (pictured here) laboratories.



Currently circulating Variants of Concern (VOC)

WHO label	Pango lineage∙	GISAID clade	Nextstrain clade	Additional amino acid changes monitored°	Earliest documented samples	Date of designation
Delta	B.1.617.2	G/478K.V1	21A, 21I, 21J	+S:K417N +S:K484K	India, Oct-2020	VOI: 4-Apr-2021 VOC: 11-May-2021
Omicron*	B.1.1.529	GR/484A	21K	+S:R346K	Multiple countries, Nov-2021	VUM: 24-Nov-2021 VOC: 26-Nov-2021

https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ accessed 18 March 2022

•Includes all descendant lineages. See the cov-lineages.org and the Pango network websites for further details.

• Only found in a subset of sequences

Previously circulating Variants of Concern

WHO label	Pango lineage●	GISAID clade	Nextstrain clade	Earliest documented samples	Date of designation
Alpha	B.1.1.7	GRY	20I (V1)	United Kingdom, Sep-2020	VOC: 18-Dec-2020 Previous VOC: 09-Mar-2022
Beta	B.1.351	GH/501Y.V2	20H (V2)	South Africa, May-2020	VOC: 18-Dec-2020 Previous VOC: 09-Mar-2022
Gamma	P.1	GR/501Y.V3	20J (V3)	Brazil, Nov-2020	VOC: 11-Jan-2021 Previous VOC: 09-Mar-2022

https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ accessed 18 March 2022

• Includes all descendant lineages. See the cov-lineages.org and the Pango network websites for further details.

Submission of routine specimens for sequencing

- representative of multiple geographic regions (provinces/districts/health facilities) from individuals of
 - all ages
 - over as many time periods during the SARS-CoV-2 epidemic in South Africa
- requested that testing laboratories in both the private and public sectors, submit respiratory samples to their closest NGS-SA sequencing laboratory on a routine basis (ideally every week) as follows, depending on the capacity of the testing laboratory:
 - All positives samples should be sent every week (NGS-SA laboratory will perform random sampling as described below) OR
 - A weekly selection of approximately 10%-20% of randomly selected positive samples should be sent every week. Number of selected samples will depend on the size of laboratory and how many other laboratories are drained by the submitting laboratory.

Submission of special interest specimens for sequencing

In addition to routine samples mentioned above, please send specimens separately to above and clearly marked if:

- Suspected vaccine breakthrough (≥14 days after vaccine), especially if hospitalised and clinically severe
- Suspected re-infection (≥90 days after previous episode), especially if hospitalised and clinically severe
- Prolonged shedding with high SARS-CoV-2 viral loads (i.e. Ct values less than 30 for more than 1 month post-primary diagnosis) in immunocompromised individuals
- Possible animal-to-human transmission
- Suspected cases of importation from another country, especially countries known to harbour SARS-CoV-2 variants of concern or countries with little available information
- Clusters of "unusual" cases (e.g., in terms of disease presentation, patient groups affected, etc.)